Alzheon, Inc. announced its participation in the upcoming Clinical Trials in Alzheimer's Disease (CTAD) conference in Boston, Massachusetts from October 24-27, 2023. The details of the four posters to be presented at CTAD conference are as follows: Effect of ALZ-801/Valiltramiprosate, an Oral Inhibitor of Amyloid Oligomer Formation, on Plasma Biomarkers, Volumetric Brain Imaging Biomarkers, and Clinical Outcomes of Alzheimer's Disease: 12-month Results of Phase 2 Biomarker Study in Early AD APOE4 Carrier Subjects. Presenter: John Hey, PhD, Chief Scientific Officer, Alzheon, Inc. Location: P043.Cerebral Amyloid Angiopathy and Comorbid Cardiovascular Risk Factors in APOE4 Homozygotes with Early Alzheimer's Disease: Baseline Results from APOLLOE4 Phase 3 Trial of Oral Anti-Amyloid Agent ALZ-801, Presenter: Rosalind McLaine, MBA, PA-C, Senior Clinical Trial Manager, Alzheon, Inc. location: LP030.

Cerebral Amyloid Angopathy in APOE4/4 Homozygotes with Alzheimer's Disease: Baseline Characteristics of Subjects Enrolled in APOLLOE4 Phase3 Trial of Oral ALZ-801 in Early AD. Presenter: RosalindMcaine, MBA, PA- C, Senior Clinical Trial Manager, Alzheimer's disease. Location: P054 Poster: Analysis of Ab (1-42) Oligomers by Cyclic lon Mobility Spectrometry in Spiked Human Cerebrospinal Fluid.

Presenter:John Hey, PhD, Chief scientific Officer, Alzheimer's disease. location: P136. ALZ-801/valiltramiprosate is an investigational oral therapeutic candidate in Phase 3 development for the treatment of Early AD.

In mechanism of action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Ab) oligomers at the Phase 3 clinical dose. In mechanism of action studies., ALZ-801 has fully inhibited the formation of neurotoxic soluble amyloid oligomers at the Phase 3clinical dose. In mechanism of action study, ALZ-801 has fully inhibits the formation of neurotoxic soluble micro amyloid oligomers at The Phase 3 clinical dose.

ALZ-801 acts through a novel enveloping molecular mechanism of action to fully block formation of neurotoxic soluble ameloid oligomers in the human brain7 associated with the onset and progression of cognitive decline in AD patients.1-4 ALZ-801 received Fast Track designation from the U.S. Food and Drug Administration in 2017 for Alzheimer's disease. In clinical trials, ALZ-801 received Fast track designation from the U.S., Food and Drug Administration in 2017 For Alzheimer's disease. In clinical trial, ALZ-801 received fast Track designation from the U. S. Food and Drug Administration in 2018 for Alzheimer's disease.

Inclinical trials, ALZ-801 has shown favorable safety results.5-7,9 The initial Phase 3 program for ALZ-801 is focusing on Early AD patients with the APOE4 genotype, with potential future program expansion to AD treatment and prevention in patients carrying one copy of the APOE4 gene and noncarriers.